SCHEMBL23804690

SCHEMBL23804690

Cc1cccc(-c2ccn(-c3nc(N4CCOCC4)c4oc(C(=O)O)cc4n3)n2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 5/20 0.43
PIK3CA P42336 6/20 0.42
MTOR P42345 2/20 0.42
PIK3R1 P27986 2/20 0.39
GRIN2B Q13224 1/20 0.39
STK4 Q13043 1/20 0.38
STK3 Q13188 1/20 0.38
LRRK2 Q5S007 1/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
TSHR P16473 2/20 0.38
HSD17B10 Q99714 2/20 0.38
LMNA P02545 1/20 0.38
MAPK1 P28482 1/20 0.38
NR5A2 O00482 1/20 0.37
NPC1 O15118 1/20 0.37
MAPT P10636 1/20 0.37
CASP3 P42574 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23815286 0.92 PIK3CA (0.41) EGLN1PIK3CAMTORPIK3R1GRIN2B
SCHEMBL30370228 0.92 PIK3CA (0.41) EGLN1PIK3CAMTORPIK3R1GRIN2B
SCHEMBL30369893 0.92 KMT2A (0.41) EGLN1PIK3CAMTORGRIN2BSTK4
SCHEMBL23815455 0.92 KMT2A (0.41) EGLN1PIK3CAMTORGRIN2BSTK4
SCHEMBL30370156 0.92 PIK3CA (0.41) EGLN1PIK3CAMTORPIK3R1GRIN2B
SCHEMBL23815458 0.92 PIK3CA (0.41) EGLN1PIK3CAMTORPIK3R1GRIN2B
SCHEMBL24711217 0.91 PIK3CA (0.40) EGLN1PIK3CAMTORPIK3R1GRIN2B
SCHEMBL23804730 0.91 PIK3CA (0.42) EGLN1PIK3CAMTORPIK3R1GRIN2B
SCHEMBL23815380 0.90 PIK3CA (0.40) EGLN1PIK3CAMTORGRIN2BSTK4
SCHEMBL23815374 0.90 PIK3CA (0.40) EGLN1PIK3CAMTORGRIN2BSTK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230146395-A1 Substituted Pyrimidines and Uses Thereof Verge Analytics, Inc. (US) 2023-05-11 US disclosed
US-20230146395-A1 Substituted Pyrimidines and Uses Thereof Verge Analytics, Inc. (US) 2023-05-11 US disclosed
US-20230146395-A1 Substituted Pyrimidines and Uses Thereof Verge Analytics, Inc. (US) 2023-05-11 US disclosed
EP-4118087-A1 SUBSTITUTED FURO[3,2-D]PYRIMIDINES AND USES THEREOF Verge Analytics, Inc. (US) 2023-01-18 EP disclosed
WO-2022261068-A1 METHODS AND TREATMENT OF VIRAL INFECTION WITH SUBSTITUTED FURO-PYRIMIDINES Verge Analytics, Inc. (US) 2022-12-15 WO disclosed
WO-2021183439-A1 SUBSTITUTED FURO[3,2-D]PYRIMIDINES AND USES THEREOF Verge Analytics, Inc. (US) 2021-09-16 WO disclosed
WO-2021183439-A1 SUBSTITUTED FURO[3,2-D]PYRIMIDINES AND USES THEREOF Verge Analytics, Inc. (US) 2021-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230146395-A1 Substituted Pyrimidines and Uses Thereof PIKFYVE, PIK3CA, PIK3CB EGLN1 3478/4885PIK3CA 2/4885MTOR 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.